In this interview recorded at the MAPS 2023 Annual Meeting in Nashville, MAPS speaks with Jim Wilkinson, PhD, Vice President, Global & US Medical Affairs, Amgen, about how to develop Medical Affairs talent into tomorrow’s leaders.
While the value of patient engagement is increasingly recognised in the clinical and launch phases of drug development, it is still a relatively new concept to involve patients in the early discovery phase. By understanding the burden of disease and patient’s aspirations for new treatments from the outset, pharma companies can ensure they are developing medicines that matter to patients. As experts in the disease area and therapeutic landscape, Medical Affairs are well placed to initiate and develop effective patient partnerships to ensure that the patient voice is incorporated during early discovery and beyond.
In this webinar we will explore practical approaches to engaging patients in early development, introducing key resources and discussing best practices. These discussions will be tailored to meet the needs of all Medical Affairs colleagues, regardless of experience.
MAPS announces the election of Dr. Danie du Plessis as Chair of the MAPS Board of Directors. Du Plessis is currently Executive Vice-President (EVP) & Head of Medical Affairs at Kyowa Kirin International and is a senior pharmaceutical executive with 30 years’ experience.
Medical Information is a critical conduit with healthcare providers who interact with field sales or scientific professionals or who seek scientific information independently. In this customer-facing and customer-focused capacity, Medical Information is the “face” of the manufacturer to many external customers and serves to facilitate the safe and effective use of the marketed products. Medical Information has a significant role in supporting the information needs of HCPs, patients, and caregivers through the provision of medical information in response to unsolicited questions about the manufacturer’s products and strives to provide excellent customer service based on the customer’s expectations through a variety of channels. MedInfo also partners with internal business functions, including, but not limited to: Medical Affairs, Pharmaceutical and Clinical Development, Quality Assurance, Manufacturing, Publication Planning, Safety, Business Technology, Finance, Legal, Regulatory, and Commercial/Marketing.
This Standard and Guidance is intended to inform learners about the Medical Information (MI) function, strategic direction, and operations across multiple geographies.
This White Paper draws on the expertise of 10 senior Medical Affairs leaders across diverse global organizations to describe the role of Medical Affairs in ensuring the MedTech industry meets the challenges of high-quality evidence, objective measures, changes in the healthcare landscape, and more.
Medical Affairs professionals want to share Real-World Evidence (RWE) about drug products with payers, patient advocates and others, but communications about drug products are highly regulated. Federal laws, including FDAMA Section 114, FDA guidance materials and FDA enforcement actions all provide insight into the types of communications FDA will and will not accept. This presentation will provide insights into the types of communications that FDA has indicated are or are not permissible, and the uncertainties that still remain.
By using the framework of Explore, Educate, Embrace we can shape our approach to Health Equity by incorporating it into our daily work.
In late January, MAPS published an article by Rahul Mandlik describing the use of ChatGPT in Medical Affairs. The result was a LinkedIn Discussion with over 40,000 views in its first 6 days. During this webinar, thought leaders in this space vision how ChatGPT may augment or, at times, undermine the practice of Medical Affairs in areas such as Medical Information, Omnichannel engagement and more. This is your chance to engage in the discussion of this absolutely cutting-edge topic. Is ChatGPT just another techno-fad? Will it fundamentally transform the Medical Affairs? What are the opportunities and dangers of this new technology? Bring your questions and join us for this interactive session.
In today’s episode, we’ll be looking at considerations for Medical Affairs in Rare Disease and Gene Therapy
Streamlining the diagnostic odyssey requires educating medical professionals to recognize “rare encounters” and engage these patients with precision and compassion.